MetaCap

Achieve Life Sciences Cash Flow Statement

NASDAQ: QUITHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

5.56-0.31 (-5.28%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Achieve Life Sciences free cash flow

In fiscal 2025, Achieve Life Sciences generated -$49.5 million of operating cash flow and spent $3,000 on capital expenditures. That left free cash flow of -$49.5 million.

Summary generated from market data by MetaCap's automated system. Methodology

Achieve Life Sciences cash flow statement (annual)

Achieve Life Sciences annual cash flow statement
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31FY 20222022-12-31FY 20212021-12-31FY 20202020-12-31FY 20192019-12-31FY 20182018-12-31FY 20172017-12-31FY 20162016-12-31
Net Income-54.65M-39.83M-29.82M-42.35M-33.15M-14.73M-16.39M-12.69M-10.58M-1.23M
Net Income growth (YoY)——————————
Depreciation & Amortization228.00K229.00K228.00K236.00K250.00K255.00K31.00K60.00K59.00K188.00K
Stock-Based Compensation8.76M5.33M3.44M3.27M2.19M1.29M1.20M854.00K348.00K1.65M
Change in Working Capital—567.00K134.00K-132.00K281.00K-979.00K908.00K-86.00K-363.00K-12.04M
Operating Cash Flow-49.47M-29.77M-24.48M-37.57M-29.44M-13.47M-15.22M-10.62M-9.11M-202.00K
Capital Expenditures-3.00K—-21.00K——-17.00K-53.00K-46.00K—-46.00K
Investing Cash Flow6.11M-21.58M-21.00K——-17.00K5.04M-5.13M12.65M10.61M
Financing Cash Flow51.53M48.53M15.28M19.32M36.61M32.68M17.32M19.76M2.00M150.00K
Net Change in Cash8.18M-2.82M-9.22M-18.25M7.17M19.19M7.15M4.01M5.54M-52.00K
Free Cash Flow-49.47M-29.77M-24.50M-37.57M-29.44M-13.49M-15.27M-10.67M-9.11M-248.00K

This table shows 10 annual periods of Achieve Life Sciences's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow QUIT's reporting calendar. What is a cash flow statement?

More financial data